Clinical review: Vasopressin and terlipressin in septic shock patients

Anne Delmas, Marc Leone, Sébastien Rousseau, Jacques Albanèse, Claude Martin, Anne Delmas, Marc Leone, Sébastien Rousseau, Jacques Albanèse, Claude Martin

Abstract

Vasopressin (antidiuretic hormone) is emerging as a potentially major advance in the treatment of septic shock. Terlipressin (tricyl-lysine-vasopressin) is the synthetic, long-acting analogue of vasopressin, and has comparable pharmacodynamic but different pharmacokinetic properties. Vasopressin mediates vasoconstriction via V1 receptor activation on vascular smooth muscle. Septic shock first causes a transient early increase in blood vasopressin concentrations; these concentrations subsequently decrease to very low levels as compared with those observed with other causes of hypotension. Infusions of 0.01-0.04 U/min vasopressin in septic shock patients increase plasma vasopressin concentrations. This increase is associated with reduced need for other vasopressors. Vasopressin has been shown to result in greater blood flow diversion from nonvital to vital organ beds compared with adrenaline (epinephrine). Of concern is a constant decrease in cardiac output and oxygen delivery, the consequences of which in terms of development of multiple organ failure are not yet known. Terlipressin (one or two boluses of 1 mg) has similar effects, but this drug has been used in far fewer patients. Large randomized clinical trials should be conducted to establish the utility of these drugs as therapeutic agents in patients with septic shock.

Figures

Figure 1
Figure 1
Pituitary secretion of vasopressin. The main hypothalamic nuclei release vasopressin and corticotrophin-releasing hormone (CRH), which stimulates the secretion of adrenocorticotrophic hormone (ACTH) via the anterior pituitary gland (AP). Magnocellular neurones (MCN) and supraoptic neurones release vasopressin, which is stored in the posterior pituitary gland (PP) before its release into the circulation. CNS, central nervous system; PCN, parvocellular neurones; PVN, paraventricular nucleus of hypothalamus; SON, supraoptic nucleus of hypothalamus. Modified from Holmes and coworkers [8].
Figure 2
Figure 2
Influence of plasma osmolality and hypotension on vasopressin secretion.

References

    1. Landry DW, Levin HR, Gallant EM, Seo S, D'Alessandro D, Oz MC, Oliver JA. Vasopressin pressor hypersensitivity in vasodilatory septic shock. Crit Care Med. 1997;25:1279–1282. doi: 10.1097/00003246-199708000-00012.
    1. Okamura T, Toda M, Ayajiki K, Toda N. Receptor subtypes involved in relaxation and contraction by arginine vasopressin in canine isolated short posterior ciliary arteries. J Vasc Res. 1997;34:464–472.
    1. Landry DW, Levin HR, Gallant EM, Ashton RC, Jr, Seo S, D'Alessandro D, Oz MC, Oliver JA. Vasopressin deficiency contributes to the vasodilation of septic shock. Circulation. 1997;95:1122–1125.
    1. Gold J, Cullinane S, Chen J, Seo S, Oz MC, Oliver JA, Landry DW. Vasopressin in the treatment of milrinone induced hypotension in severe heart failure. Am J Cardiol. 2000;85:506–508. doi: 10.1016/S0002-9149(99)00783-3. A11.
    1. Laszlo FA, Laszlo F, Jr, De Wield D. Pharmacology and clinical perspectives of vasopressin antagonists. Pharmacol Rev. 1991;43:73–108.
    1. Forrest P. Vasopressin and shock. Anaesth Intensive Care. 2001;29:463–472.
    1. Krismer AC, Wenzel V, Mayr VD, Voelckel WG, Strohmenger HU, Lurie K, Lindner KH. Arginine vasopressin during cardiopulmonary resuscitation and vasodilatory shock: current experience and future perspectives. Curr Opin Crit Care. 2001;7:157–169. doi: 10.1097/00075198-200106000-00004.
    1. Holmes CL, Patel BM, Russell JA. Physiology of vasopressin relevant to management of septic shock. Chest. 2001;120:989–999. doi: 10.1378/chest.120.3.989.
    1. Malay MB, Ashton RC, Jr, Landry DW, Townsend RN. Low dose of vasopressin in the treatment of vasodilatory septic shock. J Trauma. 1999;47:699–703.
    1. Argenziano M, Chen JM, Choudhri AF, Cullinane S, Garfein E, Weinberg AD, Smith CR, Jr, Rose EA, Landry DW, Oz MC. Management of vasodilatory shock after cardiac surgery: identification of predisposing factors and use of a novel pressor agent. Thorac Cardiovasc Surg. 1998;116:973–980.
    1. Argenziano M, Choudhri AF, Oz MC, Rose EA, Smith CR, Landry DW. A prospective randomized trial of arginine vasopressin in the treatment of vasodilatory shock after left ventricular assist device placement. Circulation. 1997;Suppl:II286–II290.
    1. Argenziano M, Chen JM, Cullinane S, Choudhri AF, Rose EA, Smith CR, Edwards NM, Landry DW, Oz MC. Arginine vasopressin in the management of vasodilatory hypotension after cardiac transplantation. J Heart Transplant. 1999;18:814–817. doi: 10.1016/S1053-2498(99)00038-8.
    1. Morales DL, Gregg D, Helman DN, Williams MR, Naka Y, Landry DW, Oz MC. Arginine vasopressin in the treatment of 50 patients with post cardiotomy vasodilatory shock. Ann Thorac Surg. 2000;69:102–106. doi: 10.1016/S0003-4975(99)01197-2.
    1. Chen JM, Cullinane S, Spanier TB, Artrip JH, John R, Edwards NM, Oz MC, Landry DW. Vasopressin deficiency and pressor hypersensitivity in hemodynamically unstable organ donors. Circulation. 1999;Suppl:II244–II246.
    1. Tsuneyoshi I, Yamada H, Kakihana Y, Nakamura M, Nakano Y, Boyle WA., III Hemodynamic and metabolic effects of low dose vasopressin infusions in vasodilatory septic shock. Crit Care Med. 2001;29:487–493. doi: 10.1097/00003246-200103000-00004.
    1. Holmes CL, Walley KR, Chittock DR, Lehman T, Russell JA. The effects of vasopressin on hemodynamics and renal function in severe septic shock: a case series. Intensive Care Med. 2001;27:1416–1421. doi: 10.1007/s001340101014.
    1. Dunser MW, Mayr AJ, Ulmer H, Ritsch N, Knotzer H, Pajk W, Luckner G, Mutz NJ, Hasibeder WR. The effects of vasopressin on systemic hemodynamics in catecholamine-resistant septic and postcardiotomy shock: a retrospective analysis. Anesth Analg. 2001;93:7–13.
    1. Dunser MW, Mayr AJ, Ulmer H, Knotzer H, Sumann G, Pajk W, Friesenecker B, Hasibeder WR. Arginine vasopressin in advanced vasodilatory shock. A prospective, randomized, controlled study. Circulation. 2003;107:2313–2319. doi: 10.1161/.
    1. Patel BM, Chittock DR, Russell JA, Walley KR. Beneficial effects of short-term vasopressin infusion during severe septic shock. Anesthesiology. 2002;96:576–582. doi: 10.1097/00000542-200203000-00011.
    1. Nicolet-Barousse L, Sharshar T, Paillard M, Raphael JC, Annane D. Vasopressin: a hormone with multiple functions [in French] Méd Thér Endocrinol. 2001;7:757–764.
    1. Prengel AW, Lindner KH, Ensinger H, Grunert A. Plasma catecholamine concentrations after successful resuscitation in patients. Crit Care Med. 1992;20:609–614.
    1. Lindner KH, Strohmenger HU, Prengel AW, Ensinger H, Goertz A, Weichel T. Hemodynamic and metabolic effects of epinephrine during cardiopulmonary resuscitation in a pig model. Crit Care Med. 1992;20:1020–1026.
    1. Schultz CH, Rivers EP, Feldcamps CS, Maronitz HB, Hevert CS. A characterization of hypothalamic-pituitary-adrenal axis function during and after human cardiac arrest. Crit Care Med. 1993;21:1339–1347.
    1. Lindner KH, Strohmenger HU, Ensinger H, Hetzel WD, Ahnefeld FW, Georgieff M. Stress hormone response during and after CPR. Anesthesiology. 1992;77:662–668.
    1. Lindner KH, Haak T, Keller A, Bothner U, Lurie KG. Release of endogenous vasopressors during and after cardiopulmonary resuscitation. Heart. 1996;75:145–150.
    1. Schwartz J, Reid IA. Role of vasopressin in blood pressure regulation in conscious water-deprived dogs. Am J Physiol. 1983;244:R74–R77.
    1. American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Chest. 1992;101:1658–1662.
    1. Ruokonen E, Takala J, Kari A, Alhava E. Septic shock and multiple organ failure. Crit Care Med. 1991;19:1146–1151.
    1. Parrillo JE, Parker MM, Natanson C, Suffredini AF, Danner RL, Cunnion RE, Ognibene FP. Septic shock in humans: advances in the understanding of pathogenesis, cardiovascular dysfunction, and therapy. Ann Intern Med. 1990;113:227–242.
    1. Oliver H, Shafer E. On the physiological action of extracts of the pituitary body and certain other glandular organs. J Physiol (Lond) 1895;18:277–279.
    1. Farini F. Diabetes insipidus and opotherapy [in Italian] Gazz Osped Clin. 1913;34:1135–1139.
    1. von den Velden R. Die nierenwirkung von hypophysenextrak-ten beim menshen. Berl Klin Wochenscgr. 1913;50:2083–2086.
    1. Du Vigneaud V, Gash DT, Katsoyannis PG. A synthetic preparation possessing biological properties associated with arginine vasopressin. J Am Chem Soc. 1954;76:4751–4752. doi: 10.1021/ja01647a089.
    1. Barberis C, Mouillac B, Durroux T. Structural bases of vasopressin/oxytocin receptor function. J Endocrinol. 1998;156:223–229. doi: 10.1677/joe.0.1560223.
    1. Paillard M, Froissard M, Blanchard A, et al. Extracellular water and osnolarity [in French] Encycl Méd Chir (Elsevier, Paris) Endocrinologie-Nutrition, 10-352-A10. 1995. p. 11.
    1. Sklar AH, Schrier RW. Central nervous system mediators of vasopressin release. Physiol Rev. 1983;63:1243–1280.
    1. Bourque CW, Oliet SH, Richard D. Osmoreceptors, osmore-ception, and osmoregulation. Front Neuroendocrinol. 1994;15:231–274. doi: 10.1006/frne.1994.1010.
    1. Robertson G, Athar S, Shelton R. Osmotic control of vasopressin function. In: Andreoli TE, Grantham JJ, Rector FC Jr, editor. In Disturbances in Body Fluid Osmolality. Bethesda, MD: American Physiological Society; 1977. pp. 125–148.
    1. Shrier RW, Berl T, Anderson RJ. Osmotic and non osmotic control of vasopressin release. Am J Physiol. 1979;236:F321–F332.
    1. Wood CE, Chen HG. Acidemia stimulate ACTH, vasopressin, and heart rate responses in fetal sheep. Am J Physiol. 1989;257:R344–R349.
    1. Robertson GL, Shelton RL, Athar S. The osmoregulation of vasopressin. Kidney Int. 1976;10:25–37.
    1. Quillen EW, Jr, Cowley AW., Jr Influence of volume changes on osmolality-vasopressin relationships in conscious dogs. Am J Physiol. 1983;244:H73–H79.
    1. Leng G, Dyball RE, Russell JA. Neurophysiology of body fluid homeostasis. Comp Biochem Physiol A. 1988;90:781–788. doi: 10.1016/0300-9629(88)90699-8.
    1. Bisset GW, Chowdrey HS. Control of release of vasopressin by neuroendocrine reflexes. Q J Exp Physiol. 1988;73:811–872.
    1. Goldsmith SR, Francis GS, Cowley AW, Cohn JN. Response of vasopressin and norepinephrine to lower body negative pressure in humans. Am J Physiol. 1982;243:H970–H973.
    1. Norsk P, Ellegaard P, Videbaek R, Stadeager C, Jessen F, Johansen LB, Kristensen MS, Kamegai M, Warberg J, Christensen NJ. Arterial pulse pressure and vasopressin release in humans during lower body negative pressure. Am J Physiol. 1993;264:R1024–R1030.
    1. Trasher TN. Baroreceptor regulation of vasopressin and renin secretion: low pressure versus high pressure receptors. Front Neuroendocrinol. 1994;15:157–187. doi: 10.1006/frne.1994.1007.
    1. O'Donnell CP, Thompson CJ, Keil LC, Thrasher TN. Renin and vasopressin responses to graded reductions in atrial pressure in conscious dogs. Am J Physiol. 1994;266:R714–R721.
    1. Leng G, Brown CH, Russell JA. Physiological pathways regulating the activity of magnocellular neurosecretory cells. Prog Neurobiol. 1999;57:625–655. doi: 10.1016/S0301-0082(98)00072-0.
    1. Day TA, Randle JC, Renaud LP. Opposing α- and β-adrenergic mechanisms mediate dose-dependent actions of norepinephrine on supraoptic vasopressin neurones in vivo. Brain Res. 1985;358:171–179. doi: 10.1016/0006-8993(85)90961-8.
    1. Czaczkes JW. Physiologic studies of antidiuretic hormone by its direct measurement in human plasma. J Clin Invest. 1964;43:1625–1640.
    1. Sharshar T, Blanchard A, Paillard M, Raphael JC, Gajdos P, Annane D. Circulating vasopressin levels in septic shock. Crit Care Med. 2003;31:1752–1758. doi: 10.1097/01.CCM.0000063046.82359.4A.
    1. Leclerc F, Walter-Nicolet E, Leteurtre S, Noizet O, Sadik A, Cremer R, Fourier C. Admission plasma vasopressin levels in children with meningococcal septic shock. Intensive Care Med. 2003;29:1339–1344. doi: 10.1007/s00134-003-1868-y.
    1. Sharshar T, Carlier R, Blanchard A, Feydy A, Gray F, Paillard M, Raphael JC, Gajdos P, Annane D. Depletion of neurohypophy-seal content of vasopressin in septic shock. Crit Care Med. 2002;30:497–500. doi: 10.1097/00003246-200203000-00001.
    1. Zerbe RL, Henry DP, Robertson GL. Vasopressin response to orthostatic hypotension: etiologic and clinical implications. Am J Med. 1983;74:265–271. doi: 10.1016/0002-9343(83)90625-3.
    1. Bucher M, Hobbhahn J, Kurtz A. Cytokine-mediated downregu-lation of vasopressin V1a receptors during acute endotox-emia in rats. Am J Physiol. 2002;282:R979–R984.
    1. Thibonnier M, Roberts JM. Characterization of human platelet vasopressin receptors. J Clin Invest. 1985;76:1857–1864.
    1. Bichet DG, Razi M, Lonergan M, Arthus MF, Papukna V, Kortas C, Barjon JN. Human platelet fraction arginine-vasopressin. Potential physiological role. J Clin Invest. 1987;79:881–887.
    1. Kusano E, Tian S, Umino T, Tetsuka T, Ando Y, Asano Y. Arginine vasopressin inhibits interleukin-1 beta-stimulated nitric oxide and cyclic guanosine monophosphate production via the OXT receptor in cultured rat vascular smooth muscle cells. J Hypertens. 1997;15:627–632. doi: 10.1097/00004872-199715060-00009.
    1. Abboud FM, Floras JS, Aylward PE, Guo GB, Gupta BN, Schmid PG. Role of vasopressin in cardiovacular and blood pressure regulation. Blood Vessels. 1990;27:106–115.
    1. Wakatsuki T, Nakaya Y, Inoue I. Vasopressin modulates K+-channel activities of cultured smooth muscle cells from porcine coronary artery. Am J Physiol. 1992;263:H491–H496.
    1. Reid I. Role of vasopressin deficiency in the vasodilation of septic shock. Circulation. 1997;95:1108–1110.
    1. Luk J. Role of V1 receptors in the action of vasopressin on the baroreflex control of heart rate. Am J Physiol. 1993;265:R524–R529.
    1. Cowley AW, Jr, Switzer SJ, Guinn MM. Evidence and quantification of the vasopressin arterial pressure control system in the dog. Circ Res. 1980;46:58–67.
    1. Mohring J, Glanzer K, Maciel JA, Jr, Dusing R, Kramer HJ, Arbogast R, Koch-Weser J. Greatly enhanced pressor response to antidiuretic hormone in patients with impaired cardiovascular reflexes due to idiopathic orthostatic hypotension. J Cardiovasc Pharmacol. 1980;2:367–376.
    1. Schwartz J, Reid IA. Effect of vasopressin blockade on blood pressure regulation during hemorrhage in conscious dogs. Endocrinology. 1981;109:1778–1780.
    1. Jordan J, Tank J, Dietrich A, Clarck JP, Benton MD. Vasopressin and blood pressure in humans. Hypertension. 2000;36:E3–E4.
    1. Liard JF, Deriaz O, Schelling P, Thibonnier M. Cardiac output distribution during vasopressin infusion or dehydration in conscious dogs. Am J Physiol. 1982;243:H663–H669.
    1. Altura BM. Dose–response relationships for arginine vasopressin and synthetic analogs on three types of rat blood vessels: possible evidence for regional differences in vasopressin receptor sites within a mammal. J Pharmacol Exp Ther. 1975;193:413–423.
    1. Kerr JC, Jain KM, Swan KG, Rocko JM. Effects of vasopressin on cardiac output and its distribution in the subhuman primate. J Vasc Surg. 1985;2:443–449. doi: 10.1067/mva.1985.avs0020443.
    1. Martikainen TJ, Tenhunen JJ, Uusaro A, Ruokonen E. Vasopressin causes selective intestinal hypoperfusion and lactate release in lethal endotoxin shock [abstract] Intensive Care Med. 2002;28:S65.
    1. Karmazyn M, Manku MS, Horrobin DF. Changes of vascularreactivity induced by low vasopressin concentrations: interactions with cortisol and lithium and possible involvement of prostaglandins. Endocrinology. 1978;102:1230–1236.
    1. Suzuki Y, Satoh S, Oyama H, Takayasu M, Shibuya M. Regional differences in the vasodilator response to vasopressin in canine cerebral arteries in vivo. Stroke. 1993;24:1049–1053.
    1. Thibonnier M, Conarty DM, Preston JA, Plesnicher CL, Dweik RA, Erzurum SC. Human vascular endothelial cells express ocytocin receptors. Endocrinology. 1999;140:1301–1309. doi: 10.1210/en.140.3.1301.
    1. Okamura T, Ayajiki K, Fujioka H, Toda N. Mechanisms underlying arginine vasopressin-induced relaxation in monkey isolated coronary arteries. J Hypertens. 1999;17:673–678. doi: 10.1097/00004872-199917050-00011.
    1. Tamaki T, Kiyomoto K, He H, Tomohiro A, Nishiyama A, Aki Y, Kimura S, Abe Y. Vasodilation induced by vasopressin V2 receptor stimulation in afferent arterioles. Kidney Int. 1996;49:722–729.
    1. Jin HK, Chen YF, Yang RH, McKenna TM, Jackson RM, Oparil S. Vasopressin lowers pulmonary artery pressure in hypoxic rats by releasing atrial natriuretic peptide. Am J Med Sci. 1989;298:227–236.
    1. Walker BR, Haynes J, Jr, Wang HL, Voelkel NF. Vasopressin-induced pulmonary vasodilation in rats. Am J Physiol. 1989;257:H415–H422.
    1. Eichinger MR, Walker BR. Enhanced pulmonary arterial dilation to arginine vasopressin in chronically hypoxic rats. Am J Physiol. 1994;267:H2413–H2419.
    1. Russ RD, Walker BR. Role of nitric oxide in vasopressinergic pulmonary vasodilatation. Am J Physiol. 1992;262:H743–H747.
    1. Sai y, Okamura T, Amakata Y, Toda N. Comparison of responses of canine pulmonary artery and vein to angiotensin II, bradykinin and vasopressin. Eur J Pharmacol. 1995;282:235–241. doi: 10.1016/0014-2999(95)00343-J.
    1. Evora PR, Pearson PJ, Schaff HV. Arginine vasopressin induces endothelium dependant vasodilatation of the pulmonary artery: V1-receptor-mediated production of nitric oxide. Chest. 1993;103:1241–1245.
    1. Eisenman A, Armali Z, Enat R, Bankir L, Baruch Y. Low dose vasopressin restores diuresis both in patients with hepatorenal syndrome and in anuric patients with end-stage heart failure. J Intern Med. 1999;246:183–190. doi: 10.1046/j.1365-2796.1999.00556.x.
    1. Aiyar N, Nambi P, Crooke ST. Desensitization of vasopressin sensitive adenylate cyclase by vasopressin and phorbol esters. Cell Signal. 1990;2:153–160. doi: 10.1016/0898-6568(90)90018-6.
    1. Edwards RM, Trizna W, Kinter LB. Renal microvascular effects of vasopressin and vasopressin antagonists. Am J Physiol. 1989;256:F274–F278.
    1. McVicar AJ. Dose-response effects of pressor doses of arginine vasopressin on renal hemodynamics in the rat. J Physiol. 1988;404:535–546.
    1. Harrison-Bernard LM, Carmines PK. Juxtamedullary micro-vascular responses to arginine vasopressin in rat kidney. Am J Physiol. 1994;267:F249–F256.
    1. Tucci JR, Espiner EA, Jagger PI, Lauler DP, Thorn GW. Vasopressin in the evaluation of pituitary-adrenal function. Ann Intern Med. 1968;69:191–202.
    1. Chrousos G. The hypothalamic-pituitary-adrenal axis and immune-mediated inflammation. N Engl J Med. 1995;332:1351–1360. doi: 10.1056/NEJM199505183322008.
    1. Antoni FA. Vasopressinergic control of pituitary adrenocorticotropin secretion comes on age. Front Neuroendocrinol. 1993;14:76–122. doi: 10.1006/frne.1993.1004.
    1. Leung FW, Jensen DM, Guth PH. Endoscopic demonstration that vasopressin but not propranolol produces gastric mucosal ischaemia in dogs with portal hypertension. Gastrointest Endosc. 1988;34:310–313.
    1. Haslam RJ, Rosson GM. Aggregation of human blood platelets by vasopressin. Am J Physiol. 1972;223:958–967.
    1. Martin C, Eon B, Saux P, Aknin P, Gouin F. Renal effects of norepinephrine used to treat septic shock patients. Crit Care Med. 1990;18:282–285.
    1. Fukuoka T, Nishimura M, Imanaka H, Taenaka N, Yoshiya I, Takezawa J. Effects of norepinephrine on renal function in septic patients with normal or elevated serum lactate levels. Crit Care Med. 1989;17:1104–1107.
    1. Martin C, Papazian L, Perrin G, Saux P, Gouin F. Norepinephrine or dopamine for the treatment of hyperdynamic septic shock. Chest. 1993;103:1826–1831.
    1. Ruokonen E, Takala J, Kari A, Saxen H, Mertsola J, Hansen EJ. Regional blood flow and oxygen transport in septic shock. Crit Care Med. 1993;21:1296–1303.
    1. Cowley AW, Monos E, Guyton AC. Interaction of vasopressin and the baroreceptor reflex system in the regulation of arterial blood pressure in the dog. Circ Res. 1974;34:505–514.
    1. Fasth S, Haglund U, Hulten L, Nordgren S. Vascular responses of small intestine and liver to regional infusion of vasopressin. Acta Chir Scand. 1981;147:583–588.
    1. van Haren FMP, Rozendaal FW, van der Hoeven JG. The effect of vasopressin on gastric perfusion in catecholamine-dependent patients in septic shock. Chest. 2003;124:2256–2260. doi: 10.1378/chest.124.6.2256.
    1. Bracco D, Cholero RL, Revelly JP. Systemic and splanchnic heamodynamic effects of vasopressin administration in vasodilatory shock. Intensive Care Med. 2001;27:S137. doi: 10.1007/s001340000751. Abstract annual COngress Geneva, Switzerland.
    1. Sladen RN, Kinstner C, Germann P, Ulrich R, Landry D. Infusion of vasopressin enhances blood pressure and renal function while preserving cerebral, and splanchnic perfusion in patients in septic shock [abstract 349] Anesthesiology. 2002;96:1421.
    1. Klinzing S, Simon M, Reinhart K, Bredle DL, Meier-Hellmann A. High-dose vasopressin is not superior to norepinephrine in septic shock. Crit Care Med. 2003;31:2646–2650. doi: 10.1097/01.CCM.0000094260.05266.F4.
    1. Martikainen TJ, Tenhumen JJ, Uusaro A, Ruokonen E. The effects of vasopressin on systemic and splanchnic hemodynamics and metabolism in endotoxin shock. Anesth Analg. 2003;97:1756–1763. doi: 10.1213/01.ANE.0000087039.60041.2E.
    1. Westphal M, Freise H, Kehrel BE, Bone HG, Van Aken H, Sielenkamper AW. Arginine vasopressin compromises gut micro-circulation in septic rates. Crit Care Med. 2004;32:194–200. doi: 10.1097/01.CCM.0000104201.62736.12.
    1. O'Brien A, Clapp L, Singer M. Terlipressin for norepinephrine-resistant septic shock. Lancet. 2002;359:1209–1210. doi: 10.1016/S0140-6736(02)08225-9.
    1. Morelli A, Rocco M, Conti G, Orecchioni A, De Gaetano A, Cortese G, Coluzzi F, Vernaglione E, Pelaia P, Pietropaoli P. Effects of terlipressin on gastric mucosa in catecholamine-dependent septic shock. Intensive Care Med. 2004.
    1. Westphal M, Stubbe H, Sielenkamper AW, Borgulya R, Van Aken H, Ball C, Bone HG. Terlipressin response in healthy and endotoxinemic sheep : impact on cardiopulonary performance and global oxygen. Intensive Care Med. 2003;29:301–308.
    1. Rodriguez-Nunez A, Fernandez-Sanmartin M, Martinon-Torres F, Gonzalez-Alonso N, Martinon-Sanchez JM. Terlipressin for catecholamine-resistant septic shock in children. Intensive Care Med. 2004;30:477–480. doi: 10.1007/s00134-003-2114-3.
    1. Dellinger RP, Carlet JM, Masur H, Gerlach H, Calandra T, Cohen J, Gea-Banacloche J, Keh D, Marshall JC, Parker MM, et al. Surviving Sepsis campaign guidelines for management of severe sepsis and septic shock. Crit Care Med. 2004;32:858–872. doi: 10.1097/01.CCM.0000117317.18092.E4.

Source: PubMed

Patrocinadores e Colaboradores

Condições médicas

Intervenções de drogas

3
Se inscrever